{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:46:29Z","timestamp":1792784789182,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T00:00:00Z","timestamp":1540080000000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Austrian Science Funds","award":["SFB54-P04"],"award-info":[{"award-number":["SFB54-P04"]}],"id":[{"id":"https:\/\/ror.org\/013tf3c58","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.addr.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T13:44:17Z","timestamp":1539351857000},"page":"36-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"special_numbering":"C","title":["Pharmacokinetics, pharmacodynamics and safety of aptamers"],"prefix":"10.1016","volume":"134","author":[{"given":"Katarina D.","family":"Kovacevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2018.10.008_bb0005","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mtm.2016.14","article-title":"From selection hits to clinical leads: progress in aptamer discovery","volume":"5","author":"Maier","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.addr.2018.10.008_bb0010","series-title":"Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs","first-page":"183","author":"Levin","year":"2007"},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10555-007-9104-9","article-title":"Osteopontin: regulation in tumor metastasis","volume":"27","author":"Wai","year":"2008","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.surg.2011.05.015","article-title":"Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells","volume":"150","author":"Talbot","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.addr.2018.10.008_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.cb.05.110189.000443","article-title":"Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors","volume":"5","author":"Erickson","year":"1989","journal-title":"Annu. Rev. Cell Biol."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0030","first-page":"668","article-title":"Tumor targeting by an aptamer","volume":"47","author":"Hicke","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.addr.2018.10.008_bb0035","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","article-title":"Discovery and development of anticancer aptamers","volume":"5","author":"Ireson","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1006\/excr.2000.5071","article-title":"The cell-surface-expressed nucleolin is associated with the actin cytoskeleton","volume":"261","author":"Hovanessian","year":"2000","journal-title":"Exp. Cell Res."},{"issue":"16_suppl","key":"10.1016\/j.addr.2018.10.008_bb0045","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/jco.2005.23.16_suppl.3064","article-title":"Update on the first phase I study of AGRO100 in advanced cancer","volume":"23","author":"Laber","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Investig. New Drugs"},{"issue":"31","key":"10.1016\/j.addr.2018.10.008_bb0055","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1016\/j.biomaterials.2011.07.004","article-title":"Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery","volume":"32","author":"Guo","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2018.10.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.59","article-title":"In vivo SELEX for Identification of Brain-penetrating Aptamers","volume":"2","author":"Cheng","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"12","key":"10.1016\/j.addr.2018.10.008_bb0065","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s11095-004-7676-4","article-title":"Pharmacokinetics and biodistribution of novel aptamer compositions","volume":"21","author":"Healy","year":"2004","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.addr.2018.10.008_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039595","article-title":"Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis","volume":"7","author":"Nastasijevic","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.addr.2018.10.008_bb0075","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1093\/nar\/gkh862","article-title":"Application of locked nucleic acids to improve aptamer in vivo stability and targeting function","volume":"32","author":"Schmidt","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.addr.2018.10.008_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081683","article-title":"Chemical modifications of nucleic acid aptamers for therapeutic purposes","volume":"18","author":"Ni","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1164\/ajrccm.159.3.9805087","article-title":"Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin","volume":"159","author":"Jilma","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.taap.2015.05.011","article-title":"Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice","volume":"287","author":"Kang","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.18632\/oncotarget.261","article-title":"Thioaptamer conjugated liposomes for tumor vasculature targeting","volume":"2","author":"Mann","year":"2011","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0969-8051(99)00103-1","article-title":"Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood","volume":"27","author":"Dougan","year":"2000","journal-title":"Nucl. Med. Biol."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/oli.2005.15.183","article-title":"Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues","volume":"15","author":"Boomer","year":"2005","journal-title":"Oligonucleotides"},{"issue":"5","key":"10.1016\/j.addr.2018.10.008_bb0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09537100903085927","article-title":"The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction","volume":"20","author":"Spiel","year":"2009","journal-title":"Platelets"},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0115","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1160\/TH07-10-0638","article-title":"Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice","volume":"99","author":"Bergmeier","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.addr.2018.10.008_bb0120","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.10.008_bb0125","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2018.10.008_bb0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.thromres.2007.03.011","article-title":"The role of von Willebrand factor in thrombus formation","volume":"120","author":"Ruggeri","year":"2007","journal-title":"Thromb. Res."},{"issue":"32","key":"10.1016\/j.addr.2018.10.008_bb0135","doi-asserted-by":"crossref","first-page":"21948","DOI":"10.1016\/S0021-9258(18)54729-3","article-title":"The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII","volume":"266","author":"Wise","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood.V73.3.706.706","article-title":"von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation","volume":"73","author":"Mayadas","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0022-2143(98)90157-3","article-title":"Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen","volume":"131","author":"Jilma","year":"1998","journal-title":"J. Lab. Clin. Med."},{"issue":"6","key":"10.1016\/j.addr.2018.10.008_bb0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-0037-1616936","article-title":"Role of von Willebrand factor in vascular disease","volume":"29","author":"Paulinska","year":"2009","journal-title":"Hamostaseologie"},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0160","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1160\/TH14-09-0731","article-title":"VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP","volume":"113","author":"Schwameis","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.addr.2018.10.008_bb0165","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/jth.13728","article-title":"Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state","volume":"15","author":"Sins","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.addr.2018.10.008_bb0170","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2018.10.008_bb0175","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.010909.105547","article-title":"Discovery and development of therapeutic aptamers","volume":"50","author":"Bouchard","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.addr.2018.10.008_bb0180","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0006-2952(97)00190-1","article-title":"Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration","volume":"54","author":"Phillips","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0185","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0190","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0195","first-page":"539","article-title":"A dose ranging phase I\/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura","volume":"106","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0200","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0205","first-page":"563","article-title":"A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease","volume":"104","author":"Jilma","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"Jilma-Stohlawetz","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0215","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/ATVBAHA.111.237529","article-title":"ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion","volume":"32","author":"Siller-Matula","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0220","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/01.STR.0000179039.76922.e8","article-title":"Use of animal models has not contributed to development of acute stroke therapies: con","volume":"36","author":"Fisher","year":"2005","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0225","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fca.12.5","article-title":"The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome","volume":"8","author":"Vavalle","year":"2012","journal-title":"Futur. Cardiol."},{"issue":"6","key":"10.1016\/j.addr.2018.10.008_bb0230","first-page":"1020","article-title":"Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects","volume":"106","author":"Siller-Matula","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"6902","key":"10.1016\/j.addr.2018.10.008_bb0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","article-title":"RNA aptamers as reversible antagonists of coagulation factor IXa","volume":"419","author":"Rusconi","year":"2002","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0240","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0245","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.addr.2018.10.008_bb0250","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1538-7836.2012.04742.x","article-title":"A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent","volume":"10","author":"Vavalle","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.addr.2018.10.008_bb0255","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1093\/eurheartj\/ehr179","article-title":"Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy","volume":"32","author":"Povsic","year":"2011","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.addr.2018.10.008_bb0260","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.addr.2018.10.008_bb0265","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1538-7836.2012.04790.x","article-title":"Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma","volume":"10","author":"Gorczyca","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"20","key":"10.1016\/j.addr.2018.10.008_bb0270","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1182\/blood-2010-10-311936","article-title":"Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor","volume":"117","author":"Waters","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0275","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Macugen","year":"2007","journal-title":"Ophthalmology"},{"issue":"22","key":"10.1016\/j.addr.2018.10.008_bb0280","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0285","first-page":"353","article-title":"Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice","volume":"19","author":"Vavvas","year":"2006","journal-title":"Ophthalmol. Clin. N. Am."},{"issue":"12","key":"10.1016\/j.addr.2018.10.008_bb0290","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"Drolet","year":"2000","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0295","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(99)00285-6","article-title":"Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys","volume":"732","author":"Tucker","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"7\u20138","key":"10.1016\/j.addr.2018.10.008_bb0300","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1345\/aph.1G604","article-title":"Pegaptanib: a novel approach to ocular neovascularization","volume":"40","author":"Chapman","year":"2006","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"10.1016\/j.addr.2018.10.008_bb0305","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1177\/0091270011412961","article-title":"Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration","volume":"52","author":"Basile","year":"2012","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-9440(10)65263-7","article-title":"Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers","volume":"154","author":"Floege","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2015.0567","article-title":"Chemically modified interleukin-6 aptamer inhibits development of collagen-induced arthritis in cynomolgus monkeys","volume":"26","author":"Hirota","year":"2016","journal-title":"Nucleic Acid Ther."},{"issue":"7","key":"10.1016\/j.addr.2018.10.008_bb0325","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1021\/bc300128r","article-title":"PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice","volume":"23","author":"Da Pieve","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0330","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11095-005-9305-2","article-title":"Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor","volume":"23","author":"McCauley","year":"2006","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0335","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cbic.200300663","article-title":"Spiegelmers: biostable aptamers","volume":"4","author":"Eulberg","year":"2003","journal-title":"Chembiochem"},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0340","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nbt0996-1116","article-title":"Mirror-design of L-oligonucleotide ligands binding to L-arginine","volume":"14","author":"Nolte","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0345","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nbt0996-1112","article-title":"Mirror-image RNA that binds D-adenosine","volume":"14","author":"Klussmann","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0350","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1074-5521(02)00111-4","article-title":"GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism","volume":"9","author":"Leva","year":"2002","journal-title":"Chem. Biol."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0355","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2353\/ajpath.2008.070601","article-title":"Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db\/db mice","volume":"172","author":"Ninichuk","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0360","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ndt\/gfv053","article-title":"A new chance to beat diabetic kidney disease: innate immunity and MCP-1: a matter of good and bad macrophages?","volume":"30","author":"Gnudi","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0365","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfv012","article-title":"Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus","volume":"30","author":"Fufaa","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0370","doi-asserted-by":"crossref","first-page":"F1288","DOI":"10.1152\/ajprenal.00316.2013","article-title":"CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice","volume":"305","author":"Sullivan","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"7","key":"10.1016\/j.addr.2018.10.008_bb0375","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfs555","article-title":"Blockade of CCL2\/CCR2 signalling ameliorates diabetic nephropathy in db\/db mice","volume":"28","author":"Seok","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"issue":"9","key":"10.1016\/j.addr.2018.10.008_bb0380","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/ki.2010.263","article-title":"CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice","volume":"78","author":"Kang","year":"2010","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/gfv459","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0390","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/039463200902200307","article-title":"Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo","volume":"22","author":"Mayr","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.addr.2018.10.008_bb0395","series-title":"Single and Repeated Dose First-In-Human Study With the Anti-Hepcidin Spiegelmer NOX-H94 [Abstract]","volume":"Vol. 5","author":"Riecke","year":"2013"},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0400","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 11","key":"10.1016\/j.addr.2018.10.008_bb0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/17.suppl_11.39","article-title":"Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines","volume":"17","author":"MacDougall","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0410","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1681\/ASN.2006080856","article-title":"Clinical aspects of iron use in the anemia of kidney disease","volume":"18","author":"Horl","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0415","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0420","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/clpt.2013.58","article-title":"Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12","volume":"94","author":"Vater","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2018.10.008_bb0425","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.addr.2018.10.008_bb0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.addr.2018.10.008_bb0435","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.addr.2018.10.008_bb0440","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1538-7836.2008.02932.x","article-title":"A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor","volume":"6","author":"Chan","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.addr.2018.10.008_bb0445","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.107.745687","article-title":"Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease","volume":"117","author":"Chan","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.addr.2018.10.008_bb0450","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"31","key":"10.1016\/j.addr.2018.10.008_bb0455","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.addr.2018.10.008_bb0460","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10016","key":"10.1016\/j.addr.2018.10.008_bb0465","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.addr.2018.10.008_bb0470","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1074-5521(02)00190-4","article-title":"Reflections on a novel therapeutic candidate","volume":"9","author":"Sooter","year":"2002","journal-title":"Chem. Biol."},{"issue":"4","key":"10.1016\/j.addr.2018.10.008_bb0475","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2017.5","article-title":"Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed\/refractory multiple myeloma: a Phase IIa Study","volume":"31","author":"Ludwig","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.addr.2018.10.008_bb0480","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2018.10.008_bb0485","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"127","article-title":"PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals","author":"Webster","year":"2009"},{"issue":"23","key":"10.1016\/j.addr.2018.10.008_bb0490","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2018.10.008_bb0495","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000620\/WC500026214.pdf (European Medicines Agency)."},{"key":"10.1016\/j.addr.2018.10.008_bb0500","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/11\/WC500135123.pdf (European Medicines Agency; 16\/11\/2012)."},{"key":"10.1016\/j.addr.2018.10.008_bb0505","unstructured":"https:\/\/globenewswire.com\/news-release\/2017\/05\/31\/1004785\/0\/en\/Novo-Nordisk-receives-US-FDA-approval-of-REBINYN-nonacog-beta-pegol-N9-GP.html (Novo Nordisk; 31\/05\/2017)."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18302588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X18302588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:46:39Z","timestamp":1775245599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X18302588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":101,"alternative-id":["S0169409X18302588"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2018.10.008","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, pharmacodynamics and safety of aptamers","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Medical University of Vienna. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}